An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma

An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma

Luciano J Costa,1 Thomas W LeBlanc,2 Hans Tesch,3 Pieter Sonneveld,4 Sarasa MA Johnson,5 Francis Vekeman,5 Patrick Hlavacek,6 Aster Meche,6 Chai Hyun Kim,6 Paul Cislo,7 David M Hughes,8 Guido Nador,9 Marco DiBonaventura6 1University of Alabama at Birmingham, Birmingham, AL, USA; 2Duke University Sch...

Full description

Saved in:
Bibliographic Details
Main Authors: Costa LJ, LeBlanc TW, Tesch H, Sonneveld P, Johnson SM, Vekeman F, Hlavacek P, Meche A, Kim CH, Cislo P, Hughes DM, Nador G, DiBonaventura M
Format: Article
Language:English
Published: Dove Medical Press 2025-06-01
Series:Blood and Lymphatic Cancer: Targets and Therapy
Subjects:
hematology
bispecific antibody
efficacy
clinical trial
electronic health record
Online Access:https://www.dovepress.com/an-updated-indirect-comparison-of-elranatamab-versus-a-real-world-exte-peer-reviewed-fulltext-article-BLCTT
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.dovepress.com/an-updated-indirect-comparison-of-elranatamab-versus-a-real-world-exte-peer-reviewed-fulltext-article-BLCTT

Similar Items